Literature DB >> 21943545

Five-year survival for lung cancer patients managed in general hospitals.

M Grivaux1, M Zureik, L Marsal, B Asselain, M Peureux, J-M Chavaillon, A Prudhomme, M Carbonnelle, E Goarant, B Maury, A Bedossa, F Blanchon.   

Abstract

INTRODUCTION: In 2000, the college of pulmonologists of general hospitals undertook an epidemiological study (KBP-2000-CPHG) enrolling all new cases of histologically confirmed lung cancer managed in general hospitals. This paper reports the 5-year survival in these cases.
METHODS: Vital status was available for 5447 out of 5667 patients included in the original study. The effect of different prognostic factors on mortality was assessed.
RESULTS: At 5 years, 567 patients (10.4%) were still alive. Median survival for the 4880 (89.6%) deceased patients was 7 months. Univariate analysis identified age, smoking history, performance status, histological type and disease stage (TMN classification) as determinants of survival. For non-small cell lung cancer (n=4885) multivariate analysis identified five predictive factors for mortality - age, gender, histological type, performance status and stage.
CONCLUSIONS: Five-year survival in lung cancer continues to be poor. As the risk factors for poor outcome at the time of diagnosis are not modifiable and pending, the results of screening studies reduction in mortality must rest on primary prevention.
Copyright © 2011 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21943545     DOI: 10.1016/j.rmr.2008.07.001

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  4 in total

1.  Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.

Authors:  Xuee Zhu; Chuanhong Liao; Bill C Penney; Feng Li; Mark K Ferguson; Cassie A Simon; Tianming Wu; Haiyan Liu; Yonglin Pu
Journal:  Nucl Med Commun       Date:  2017-02       Impact factor: 1.690

2.  Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.

Authors:  P Song; B Song; J Liu; X Wang; X Nan; J Wang
Journal:  Clin Transl Oncol       Date:  2020-09-24       Impact factor: 3.405

3.  Socioeconomic Differences and Lung Cancer Survival-Systematic Review and Meta-Analysis.

Authors:  Isabelle Finke; Gundula Behrens; Linda Weisser; Hermann Brenner; Lina Jansen
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

4.  Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China.

Authors:  Jiali Liu; Yuxiang Ma; Ruizhen Gao; Xia Liu; Yalan Wang; Juan Yu; Jianhua Zhan; Yan Huang; Huiyin Qin; Li Zhang
Journal:  BMJ Open       Date:  2022-02-14       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.